Drug recall · June 1, 2022
Tivicay recall
Why: Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.
- Lots / codes
Lot: 2A9E, Exp 1/2027
- Quantity
- 328 bottles
- Company
- GlaxoSmithKline LLC, Zebulon, NC
- Distribution
- Nationwide in the U.S.
- Initiated
- May 13, 2022 · Voluntary: Firm initiated
- Classified
- May 25, 2022
- Reported
- June 1, 2022
- Ended
- August 17, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tivicay
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.